Revolutionary solution for continuous monitoring in normal hospital wards

The development of an easy-to-use and highly scalable solution for continuous monitoring in normal hospital wards is at the centre of our mission. Our clinical wearable, about the size of a matchbox, records key vital signs such as heart rate, respiratory rate, oxygen saturation, temperature, activity level and patient position regularly and non-invasively by attaching it to the body via a patch. This innovative solution is based on a platform concept that enables easy customisation for different applications, providing a comprehensive insight into the patient's state of health.

How would you explain your solution to a healthcare professional in three sentences?

We are developing an easy-to-use and highly scalable solution for continuous monitoring in standard hospital wards. Our clinical wearable is about the size of a matchbox and, when attached to the patient's body via a plaster, regularly and non-invasively records important vital signs such as heart rate, respiratory rate, oxygen saturation, temperature, activity level and position. The idea is based on a platform concept so that the device can be easily adapted to different applications.

What problem motivated you to found the company?

There are 4.2 million deaths worldwide following surgical procedures, 72% of which occur in normal wards. Studies show that 75% of the complications that occur could be avoided by continuous monitoring in normal wards through early detection of deterioration. In addition, the burden on nursing staff can be reduced and the quality of treatment improved by gaining a more complete picture of the patient's state of health. On the other hand, patients are given a greater sense of security.

How do you convince a pharmaceutical company, a health insurer, an insurance company or another potential customer to set up a pilot project with you?

Continuous monitoring promises great benefits for patient outcomes and paves the way for clinics to digitalise. However, previous solutions often fail due to a lack of user-friendliness and severely limited scalability. Our wireless technology enables easy plug & play by allowing data to be sent instantly, making it independent of third-party devices. The individual wearables network with each other and reinforce each other. Thanks to our close connection to Charité, we have worked closely with doctors and nursing staff from the very beginning. The close connection to the Charité enables us to optimally adapt to the needs of doctors, nursing staff and patients right from the start. In addition, our previous successful medical technology start-up (Babybe) and our background mean that we have extensive expertise in the field of usability and wearables, which is incorporated here.

Thanks to the modular concept, we can generate great added value through customised solutions, including for research. For example, a joint research project with Charité will start in March, in which a cuffless, continuous blood pressure measurement function, AI artefact reduction and interactive aspects for active patient participation are to be implemented.

Who are your current customers (groups) and who are the potential customers?

As a first step, we want to focus on the inpatient sector and offer our solution on normal bed wards. In the medium term, we also see ourselves in the home care market and in nursing homes. Other areas could also become interesting for us, including in non-clinical markets, e.g. occupational safety and monitoring of vulnerable population groups in relation to heat stress, etc.

Where do you see yourselves in 3 years' time and how can 5-HT support you?

potential of our technology, but also of potential cooperation partners, especially in the field of patient monitoring, for whom our solution can add value to their existing portfolio.

You took part in the WE CARE event in November 2023. What is your impression of the event and what have you gained from participating (so far)?

Just being nominated as one of 5 finalists by care directors has shown us that we have the right approach with our technology and are on the right track. It will still be a few months before a trial order is possible, but some contacts had already expressed their interest at the event.